The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Journal Article (Clinical Trial;Journal Article)
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
- Rook, AH; Zaki, MH; Wysocka, M; Wood, GS; Duvic, M; Showe, LC; Foss, F; Shapiro, M; Kuzel, TM; Olsen, EA; Vonderheid, EC; Laliberte, R; Sherman, ML
- September 2001
Volume / Issue
- 941 /
Start / End Page
- 177 - 184
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)
- United States